LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

LLY

1,052.84

+4.37%↑

JNJ

246.03

+1.46%↑

ABBV

228.33

+1.59%↑

NVS

164.74

+1.26%↑

MRK

123.15

+0.73%↑

Home・Aktien・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

BrancheGesundheitswesen

429.9 -1.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

424.87

Max

436.84

Schlüsselkennzahlen
By Trading Economics
Einkommen	-72M -114M
Verkäufe	74M 287M
Gewinnspanne	-39.75
Angestellte	528
EBITDA	-68M -106M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+59.74% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Apr. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.4B 11B
Vorheriger Eröffnungskurs	431.49
Vorheriger Schlusskurs	429.9

Nachrichtenstimmung

By Acuity

50%

141 / 351 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

263.2 / 277.1 Unterstützung & Widerstand

Madrigal Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Feb. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. Feb. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. Feb. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. Feb. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. Feb. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. Feb. 2026, 23:21 UTC

Ergebnisse

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. Feb. 2026, 23:20 UTC

Ergebnisse

Nickel Industries 2025 Operating Profit US$126.4 Million

22. Feb. 2026, 23:19 UTC

Ergebnisse

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. Feb. 2026, 23:19 UTC

Ergebnisse

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. Feb. 2026, 23:18 UTC

Ergebnisse

Nickel Industries Won't Pay a Final Dividend

22. Feb. 2026, 23:16 UTC

Ergebnisse

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. Feb. 2026, 21:35 UTC

Ergebnisse

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. Feb. 2026, 21:34 UTC

Ergebnisse

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. Feb. 2026, 21:34 UTC

Ergebnisse

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. Feb. 2026, 21:33 UTC

Ergebnisse

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. Feb. 2026, 21:33 UTC

Ergebnisse

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol Final Dividend A$0.60/Share

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Revenue A$31.37 Billion, Down 10%

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. Feb. 2026, 14:31 UTC

Akquisitionen, Fusionen, Übernahmen

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. Feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. Feb. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. Feb. 2026, 22:12 UTC

Ergebnisse

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Feb. 2026, 21:23 UTC

Ergebnisse

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. Feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. Feb. 2026, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. Feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer-Vergleich

Kursveränderung

Madrigal Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

59.74% Vorteil

12-Monats-Prognose

Durchschnitt 694.9 USD 59.74%

Hoch 964 USD

Tief 529 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Madrigal Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Madrigal Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

263.2 / 277.1Unterstützung & Widerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

141 / 351 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.